What it's for (Indications)
- Pitavastatin is indicated as an adjunct to diet to reduce elevated total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (ApoB), and triglycerides (TG), and to increase high-density lipoprotein cholesterol (HDL-C) in adult patients with primary hyperlipidemia or mixed dyslipidemia.
- Its primary role is in the management of dyslipidemia, particularly when dietary modifications alone are insufficient, to mitigate the risk of atherosclerotic cardiovascular disease.
- Furthermore, it is indicated for the treatment of adult patients with homozygous familial hypercholesterolemia (HoFH) to reduce elevated LDL-C levels, serving as an adjunct to other established lipid-lowering treatments (e.
- g.
- , LDL apheresis) or in situations where such specialized treatments are unavailable or unsuitable.
- The efficacy in reducing cardiovascular morbidity and mortality has been consistently demonstrated across the statin class, aligning pitavastatin with these crucial long-term therapeutic goals for cardiovascular health.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The recommended starting dose of pitavastatin for adult patients with primary hyperlipidemia or mixed dyslipidemia is 2 mg orally once daily. The dosage can be adjusted based on the patient's individual lipid profiles, therapeutic response, and specific treatment goals, typically ranging from 1 mg to a maximum of 4 mg once daily. For adult patients diagnosed with homozygous familial hypercholesterolemia, the recommended initial dose is 4 mg once daily. Pitavastatin can be administered at any time of day, with or without food, though consistent daily timing is often recommended. Dosage adjustments are imperative in specific patient populations; for instance, in patients with moderate to severe renal impairment (creatinine clearance 30-59 mL/min and <30 mL/min, respectively) who are not undergoing hemodialysis, the recommended starting dose is 1 mg once daily, and the maximum daily dose should not exceed 2 mg. Concomitant use with erythromycin requires a reduced maximum pitavastatin dose of 1 mg once daily. Clinicians must carefully review all concomitant medications to prevent potential drug interactions and subsequent dose adjustments. |
Safety & Warnings
Common Side Effects
- Common side effects associated with pitavastatin use typically include myalgia (muscle pain), arthralgia (joint pain), headache, constipation, diarrhea, and nausea.
- These adverse effects are generally mild to moderate in severity and often transient.
- More serious, albeit rare, adverse effects include myopathy, which, if unaddressed, can progress to rhabdomyolysis.
- Rhabdomyolysis is a severe muscle breakdown condition that can lead to acute renal failure and other life-threatening complications.
- Patients should be explicitly advised to promptly report any unexplained muscle pain, tenderness, or weakness, especially if these symptoms are accompanied by fever, malaise, or dark urine.
- Hepatic dysfunction, characterized by elevations in serum transaminases, can also occur, necessitating regular monitoring of liver function tests.
- Other less common but significant adverse events reported with statin therapy, including pitavastatin, involve new-onset diabetes mellitus, cognitive impairment (e.
- g.
- , memory loss, forgetfulness, amnesia, confusion), and interstitial lung disease.
- Peripheral neuropathy and various hypersensitivity reactions such as rash and urticaria have also been observed.
- Comprehensive patient education and vigilant monitoring are crucial for early detection and management of these effects.
Serious Warnings
- Black Box Warning: **Serious Warnings Regarding Pitavastatin Therapy:** Pitavastatin, similar to other medications in the HMG-CoA reductase inhibitor class, does not carry an FDA-mandated Black Box Warning. However, healthcare professionals and patients must be acutely aware of several critical safety concerns that necessitate careful consideration during treatment. The most significant concern is the potential for severe muscle toxicity, including myopathy and rhabdomyolysis, which can lead to life-threatening complications such as acute renal failure. This risk is dose-dependent and substantially increased by co-administration with drugs that inhibit pitavastatin's metabolism, such as cyclosporine (which is a contraindication), gemfibrozil, and certain macrolide antibiotics like erythromycin. Patients must be diligently counseled to immediately report any unexplained muscle pain, tenderness, or weakness, especially if accompanied by malaise, fever, or dark urine, to their prescribing physician. Liver dysfunction, manifested by persistent elevations in serum transaminases, can also occur; thus, liver function tests should be conducted prior to initiation and periodically during treatment. If transaminase levels increase to more than three times the upper limit of normal and persist, pitavastatin should be discontinued. Furthermore, pitavastatin is absolutely contraindicated during pregnancy and breastfeeding due to the risk of fetal harm and the potential for serious adverse reactions in nursing infants, respectively. Women of childbearing potential are required to use effective contraception during therapy.
- Patients receiving pitavastatin therapy should be thoroughly educated about the potential for muscle pain and the rare but serious risk of myopathy and rhabdomyolysis.
- Any unexplained muscle symptoms warrant immediate medical evaluation.
- Liver function tests are strongly recommended prior to the initiation of therapy and periodically thereafter to monitor for potential hepatic dysfunction.
- Pitavastatin should be used with caution in patients with a history of liver disease or substantial alcohol consumption.
- While a dose-dependent increase in HbA1c and fasting serum glucose levels has been reported with statins, potentially contributing to new-onset diabetes mellitus, the overall cardiovascular benefits generally outweigh this risk in eligible patients.
- Rarely, immune-mediated necrotizing myopathy (IMNM), an autoimmune myopathy characterized by persistent proximal muscle weakness and elevated creatine kinase (CK) levels, has been associated with statin use, typically resolving with statin discontinuation and immunosuppressive therapy.
- Endocrine effects, including changes in glycemic control, also necessitate consideration.
- Concomitant use of pitavastatin with certain medications such as cyclosporine (contraindicated), erythromycin, gemfibrozil, and other fibrates requires careful clinical assessment and potential dose modification due to an increased risk of adverse effects, particularly muscle-related complications.
How it Works (Mechanism of Action)
Pitavastatin exerts its potent lipid-lowering effects primarily through the selective, competitive inhibition of HMG-CoA reductase. This enzyme is the rate-limiting step in the mevalonate pathway, which is responsible for endogenous cholesterol biosynthesis in the liver. By blocking this crucial enzymatic step, pitavastatin significantly reduces the intracellular supply of cholesterol within hepatocytes. This reduction in hepatic cholesterol synthesis subsequently leads to an up-regulation of low-density lipoprotein (LDL) receptors on the surface of liver cells. The increased expression of these LDL receptors enhances the uptake and catabolism of circulating LDL-C from the bloodstream, thereby lowering plasma LDL-C concentrations. Furthermore, the decrease in hepatic cholesterol also reduces the production and secretion of very low-density lipoprotein (VLDL), which is a precursor to LDL-C, contributing to a reduction in circulating triglyceride levels. While its primary action is LDL-C reduction, pitavastatin also leads to a modest increase in high-density lipoprotein cholesterol (HDL-C), further contributing to its beneficial lipid profile modification. Its unique chemical structure contributes to its high potency and relatively long duration of action within the liver.
Commercial Brands (Alternatives)
No other brands found for this formula.